CANbridge Pharmaceuticals Inc.

HKEX:1228.HK

0.22 (HKD) • At close November 13, 2024
Bedrijfsnaam CANbridge Pharmaceuticals Inc.
Symbool 1228.HK
Munteenheid HKD
Prijs 0.219
Beurswaarde 93,039,592
Dividendpercentage 0%
52-weken bereik 0.187 - 1.39
Industrie Biotechnology
Sector Healthcare
CEO Dr. James Qun Xue M.B.A., Ph.D.
Website https://www.canbridgepharma.com

An error occurred while fetching data.

Over CANbridge Pharmaceuticals Inc.

CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy for the treatment of Hunter syndrome; NERLYNX (Neratinlib), a potent irreversible tyrosine kinase inhibitor for HER2-positive breast cancer; and Caphosol

Vergelijkbare Aandelen

Honliv Healthcare Management Group Company Limited logo

Honliv Healthcare Management Group Company Limited

9906.HK

2.06 HKD

Wenzhou Kangning Hospital Co., Ltd. logo

Wenzhou Kangning Hospital Co., Ltd.

2120.HK

12.76 HKD

Zhongzhi Pharmaceutical Holdings Limited logo

Zhongzhi Pharmaceutical Holdings Limited

3737.HK

0.92 HKD

MOG Holdings Limited logo

MOG Holdings Limited

1942.HK

1.36 HKD

Guangdong Kanghua Healthcare Co., Ltd. logo

Guangdong Kanghua Healthcare Co., Ltd.

3689.HK

2.17 HKD

Kangji Medical Holdings Limited logo

Kangji Medical Holdings Limited

9997.HK

5.95 HKD

Kintor Pharmaceutical Limited logo

Kintor Pharmaceutical Limited

9939.HK

1.25 HKD

Beijing Tong Ren Tang Chinese Medicine Company Limited logo

Beijing Tong Ren Tang Chinese Medicine Company Limited

3613.HK

8.16 HKD

Financiële Gegevens

Cijfers zijn in miljoenen (HKD)

Cijfers zijn in miljoenen (HKD)